Quote | Immix Biopharma Inc. (NASDAQ:IMMX)
Last: | $1.98 |
---|---|
Change Percent: | 0.0% |
Open: | $2.13 |
Close: | $1.98 |
High: | $2.1379 |
Low: | $1.96 |
Volume: | 159,581 |
Last Trade Date Time: | 06/28/2024 03:00:00 am |
News | Immix Biopharma Inc. (NASDAQ:IMMX)
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
Message Board Posts | Immix Biopharma Inc. (NASDAQ:IMMX)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $IMMX 24% v3,1M c2.30 f13,898M H2.39 ML1.51 | znewcar1 | investorshangout | 04/27/2023 8:46:40 PM |
Thank you, bro, this one needs a pin | subslover | investorshub | 04/27/2023 9:43:09 AM |
$IMMX 5:30 NEWS https://finance.yahoo.com/news/nexcella-immix-biopharma-subsidiar | TheFinalCD | investorshub | 04/26/2023 9:56:46 PM |
N excella, an Immix Biopharma subsidiary, Announces Positive | Awl416 | investorshub | 04/26/2023 9:33:44 PM |
Play the volume spikes an thats it or | harry crumb | investorshub | 03/29/2023 2:00:43 PM |
News, Short Squeeze, Breakout and More Instantly...
Immix Biopharma Inc. Company Name:
IMMX Stock Symbol:
NASDAQ Market:
LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced t...
92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis patients enrolled in NEXICART-1: 12 out of 12 patients not exposed to prior BCMA-targeted bispecific responded to NXC-201 (100% ORR), of which 9 out of 12 were complete responders (75% CRs) 1 patient wi...